Elvira De Leonibus

Elvira De Leonibus Associate Principal Investigator Head of Behavioral Core Other positions: Principal Investigator, Neuropsychopharmacology Lab, Institute of Biochemistry and Cellular Biology, National Research Council, Italy Elvira De Leonibus graduated in Developmental Psychology and did her PhD in Psychobiology and Psychopharmacology at “La Sapienza”, Rome. She then moved to the Catholic University of Nijmegen (The Netherlands) for a post-doctoral position. Her main research interest has been the neurobiology of learning and memory in normal and pathological conditions. In 2007, she joined the TIGEM with a semi-independent research appointment to contribute her expertise in pre-clinical research to the discovery of novel genetic and pharmacological therapeutic approaches for human genetic disorders. Since 2010, she has held a full appointment as Group Leader of the Neuropsychopharmacology lab at National Research Council (CNR). From 2014, this role has been held with a joint appointment as a member of the TIGEM Faculty. Supported by grants from the American Alzheimer Association, San Filippo Foundations, MPS Society, Cure SanFilippo etc, she has identified early cognitive deficits in Parkinson’ disease, ageing, and Alzheimer’ disease regulated by glutamate-dopamine interaction in cortical and subcortical regions. More recently, her work has identified altered dopamine signalling responsible for early behavioural deficits in the lysosomal storage disorders, mucopolysaccharidosis type IIIA and II. Her work is also currently focused on the neurobiology and neuropharmacology of sex-differences in normal cognitive functions and in neurodegenerative disorders. To reach these aims her research combines in vivo (optogenetics, chemogenetics, electrophysiology, pharmacology) and in vitro (primary neuronal cultures, reprogrammed neurons etc) innovative approaches. https://www.tigem.it/research/research-faculty/de-leonibus https://www.tigem.it/logo.png

Biography Research Interests Core Facility Research Group Publications

Associate Principal Investigator
Head of Behavioral Core

Other positions:
Principal Investigator, Neuropsychopharmacology Lab, Institute of Biochemistry and Cellular Biology, National Research Council, Italy

Elvira De Leonibus graduated in Developmental Psychology and did her PhD in Psychobiology and Psychopharmacology at “La Sapienza”, Rome. She then moved to the Catholic University of Nijmegen (The Netherlands) for a post-doctoral position. Her main research interest has been the neurobiology of learning and memory in normal and pathological conditions. In 2007, she joined the TIGEM with a semi-independent research appointment to contribute her expertise in pre-clinical research to the discovery of novel genetic and pharmacological therapeutic approaches for human genetic disorders. Since 2010, she has held a full appointment as Group Leader of the Neuropsychopharmacology lab at National Research Council (CNR). From 2014, this role has been held with a joint appointment as a member of the TIGEM Faculty.

Supported by grants from the American Alzheimer Association, San Filippo Foundations, MPS Society, Cure SanFilippo etc, she has identified early cognitive deficits in Parkinson’ disease, ageing, and Alzheimer’ disease regulated by glutamate-dopamine interaction in cortical and subcortical regions. More recently, her work has identified altered dopamine signalling responsible for early behavioural deficits in the lysosomal storage disorders, mucopolysaccharidosis type IIIA and II. Her work is also currently focused on the neurobiology and neuropharmacology of sex-differences in normal cognitive functions and in neurodegenerative disorders. To reach these aims her research combines in vivo (optogenetics, chemogenetics, electrophysiology, pharmacology) and in vitro (primary neuronal cultures, reprogrammed neurons etc) innovative approaches.

Targeting Early disease mechanisms in neurodegenerative disorders

Neurodegenerative disorders are characterized by progressive neuropathological processes that can last decades before a conspicuous loss of neurons can be detected. Therefore, there is a large therapeutic window to find early subtle behavioural and cognitive symptoms that allow early diagnosis and the discovery of the disease mechanisms leading to neuronal loss. Our group is interested in the identification of these early behavioural and synaptic alterations, through sensitive behavioural tasks for rodents. Using a top-down approach we move from the behavioural defects to the neuronal, biochemical and molecular mechanisms which underlie them, to finally targeting these defects with small molecules and provide proof-of concept pre-clinical evidence of their therapeutic efficacy. Using this top-down research strategy, we are working on:

The identification of early cognitive and emotional deficits in animal models of age-related neurodegenerative disorders (Ageing, Alzheimer’ disease and Parkinson’ disease) focusing on the interaction between glutamate-dopamine transmission and its modulation by autophagy.
The identification of early behavioural and synaptic changes in lysosomal storage disorders with altered signalling of heparan sulfate, focusing on dopamine signalling.

The neurobiology of memory capacity

We are currently investigating a little-explored aspect of memory processes, which is the neurobiology of memory load capacity, i.e., the number of items that a subject can remember for a short time interval, in normal and pathological conditions. We have developed novel behavioural tasks to study MC in rodents and demonstrated that mice have a limited MC of about 6 objects and that high memory load processing requires post-translational modification of glutamate receptors in the hippocampus. We recently showed that MC is impaired in early ageing and can be rescued by autophagy enhancers. Through a combination of behavioural, genetic, pharmacological and molecular approaches we are providing novel insights into (i) the role of specific brain regions and dopamine-regulated molecular pathways in supporting memory load capacity, (ii) disease mechanisms leading to memory capacity dysfunctions in schizophrenia and neurodegenerative disorders and (iii) sex-differences in memory capacity.

Elvira De Leonibus is the Head of the Behavioral Core Facility, aiming at identifying abnormal behaviors in animal models that may be associated with gene deletions or mutations pertaining to our human genetic diseases of interest

Molecular Therapy

Brunella Mongiardi

PhD Student

[email protected]

Molecular Therapy

Cristina Somma

PhD Student

[email protected]

Molecular Therapy

Maria Sanzari

PhD Student

[email protected]

Molecular Therapy

Mariagrazia Monaco

Fellow

[email protected]

Molecular Therapy

Diletta Cavezza

[email protected]

Molecular Therapy

Pina Marotta

Research Fellow

[email protected]

Thalamo-hippocampal pathway regulates incidental memory capacity in mice. Nature Commun, 2022
Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders. Nature Communications, 2021
Mechanisms by which autophagy regulates memory capacity in ageing. Aging Cell, 2020
α-synuclein overexpression in the retina leads to degeneration of dopamine amacrine cells impairing vision. Scientific Reports, 2020
Motor learning and metaplasticity in striatal neurons: relevance for Parkinson's disease. Brain, 2018

Complete List of Published Work in MyBibliography

Quote

My group aims to identify early behavioural and disease mechanisms in animal models of complex human disorders, with the ultimate goal of discovering and testing novel therapeutic strategies to manage them.

Additional Funding

MPS - THE NATIONAL MPS SOCIETY - Targeting sleep disorders in MPS-IIIA with sustainable strategies (2024-2027)
CSFF - CURE SANFILIPPO FOUNDATION - Polyamine Balance as a Driver and Marker of Neurodegeneration in MPS III (2026-2027)
CSFF - CURE SANFILIPPO FOUNDATION - The role of heparan sulfate and dopamine as disease’ modifiers in Mucopolysaccharidosis type IIIA